Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Dave Carter

Showing results (1-10 of 13) with videos related to

Pageof 2
Sort By:
Occupational Health & Safety (Waco, Tex.)|October 4, 2018
Real Threat or False Alarm: Aare You Prepared for the Next Time the Fire Alarm Sounds?Dave Carter
Studies in Health Technology and Informatics|May 17, 2025
Automatic Annotation of Disposition Counts in News ArticlesSimon Rodier, Dave Carter
Studies in Health Technology and Informatics|June 24, 2020
Global Public Health Surveillance Using Media Reports: Redesigning GPHINDave Carter, Marta Stojanovic, Philip Hachey, et al.
Journal of Extracellular Vesicles|December 12, 2018
Essentials of extracellular vesicles: posters on basic and clinical aspects of extracellular vesiclesRienk Nieuwland, Juan Manuel Falcon-Perez, Carolina Soekmadji, et al.
NDT Plus|May 8, 2015
A meta-analysis of the relative doses of erythropoiesis-stimulating agents in patients undergoing dialysisXavier Bonafont, Andreas Bock, Dave Carter, et al.
Cancer Chemotherapy and Pharmacology|November 6, 2013
A phase 1b clinical trial of the multi-targeted tyrosine kinase inhibitor lenvatinib (E7080) in combination with everolimus for treatment of metastatic renal cell carcinoma (RCC)Ana M Molina, Thomas E Hutson, James Larkin, et al.
Nephron. Clinical Practice|April 15, 2009
Impact of vitamin D dose on biochemical parameters in patients with secondary hyperparathyroidism receiving cinacalcetMartin Wilkie, Giuseppe Pontoriero, Fernando Macário, et al.
Clinical Journal of the American Society of Nephrology : CJASN|January 8, 2008
The OPTIMA study: assessing a new cinacalcet (Sensipar/Mimpara) treatment algorithm for secondary hyperparathyroidismPiergiorgio Messa, Fernando Macário, Magdi Yaqoob, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 12, 2024
Olaparib as Treatment Versus Nonplatinum Chemotherapy in Patients With Platinum-Sensitive Relapsed Ovarian Cancer: Phase III SOLO3 Study Final Overall Survival ResultsGiovanni Scambia, Ricardo Villalobos Valencia, Nicoletta Colombo, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|March 20, 2026
Adverse event profile following maintenance olaparib in patients with BRCA-mutated platinum-sensitive relapsed serous ovarian cancer in the phase III SOLO2 trialJonathan A Ledermann, Alain Lortholary, Richard T Penson, et al.
Pageof 2

Showing results (1-10 of 13) with videos related to

Sort By:
Pageof 2
Occupational Health & Safety (Waco, Tex.)|October 4, 2018
Real Threat or False Alarm: Aare You Prepared for the Next Time the Fire Alarm Sounds?Dave Carter
Studies in Health Technology and Informatics|May 17, 2025
Automatic Annotation of Disposition Counts in News ArticlesSimon Rodier, Dave Carter
Studies in Health Technology and Informatics|June 24, 2020
Global Public Health Surveillance Using Media Reports: Redesigning GPHINDave Carter, Marta Stojanovic, Philip Hachey, et al.
Journal of Extracellular Vesicles|December 12, 2018
Essentials of extracellular vesicles: posters on basic and clinical aspects of extracellular vesiclesRienk Nieuwland, Juan Manuel Falcon-Perez, Carolina Soekmadji, et al.
NDT Plus|May 8, 2015
A meta-analysis of the relative doses of erythropoiesis-stimulating agents in patients undergoing dialysisXavier Bonafont, Andreas Bock, Dave Carter, et al.
Cancer Chemotherapy and Pharmacology|November 6, 2013
A phase 1b clinical trial of the multi-targeted tyrosine kinase inhibitor lenvatinib (E7080) in combination with everolimus for treatment of metastatic renal cell carcinoma (RCC)Ana M Molina, Thomas E Hutson, James Larkin, et al.
Nephron. Clinical Practice|April 15, 2009
Impact of vitamin D dose on biochemical parameters in patients with secondary hyperparathyroidism receiving cinacalcetMartin Wilkie, Giuseppe Pontoriero, Fernando Macário, et al.
Clinical Journal of the American Society of Nephrology : CJASN|January 8, 2008
The OPTIMA study: assessing a new cinacalcet (Sensipar/Mimpara) treatment algorithm for secondary hyperparathyroidismPiergiorgio Messa, Fernando Macário, Magdi Yaqoob, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 12, 2024
Olaparib as Treatment Versus Nonplatinum Chemotherapy in Patients With Platinum-Sensitive Relapsed Ovarian Cancer: Phase III SOLO3 Study Final Overall Survival ResultsGiovanni Scambia, Ricardo Villalobos Valencia, Nicoletta Colombo, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|March 20, 2026
Adverse event profile following maintenance olaparib in patients with BRCA-mutated platinum-sensitive relapsed serous ovarian cancer in the phase III SOLO2 trialJonathan A Ledermann, Alain Lortholary, Richard T Penson, et al.
Pageof 2